Sign In
Buy ELOX
$0.370
+0 (+0%)
At Close: Jun 03, 2026
Contrasting Eloxx Pharmaceuticals (NASDAQ:ELOX) & Prime Medicine (NYSE:PRME)
01:18am, Monday, 26'th Jan 2026
Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) and Prime Medicine (NYSE: PRME - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies
Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)
01:30am, Thursday, 22'nd Jan 2026
Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch Therapeuti
Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)
01:30am, Thursday, 22'nd Jan 2026
Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17
Critical Contrast: Cortexyme (NASDAQ:CRTX) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)
01:32am, Tuesday, 30'th Dec 2025
Valuation and Earnings This table compares Eloxx Pharmaceuticals and Cortexyme"s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share
Cortexyme (NASDAQ:CRTX) versus Eloxx Pharmaceuticals (NASDAQ:ELOX) Critical Contrast
02:50am, Sunday, 28'th Dec 2025
Insider and Institutional Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Elo
Cortexyme (NASDAQ:CRTX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey
02:30am, Tuesday, 02'nd Dec 2025
Institutional and Insider Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of Elo
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
11:46am, Thursday, 11'th Jul 2024
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
07:30am, Tuesday, 16'th Apr 2024
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
11:42am, Wednesday, 13'th Mar 2024
BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an e
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
11:33am, Wednesday, 13'th Mar 2024
BARCELONA, Spain & WATERTOWN, Mass.--(BUSINESS WIRE)--Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agr
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
08:48am, Tuesday, 05'th Dec 2023
While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically, compa
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
04:15pm, Monday, 13'th Nov 2023
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome
ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:00am, Tuesday, 19'th Sep 2023
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has ent
Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans
